

AD_____

AWARD NUMBER: W81XWH-11-1-0303

TITLE: The Role of Retinal Determination Gene Network (RDGN) in Hormone Signaling Transduction and Prostate Tumorigenesis

PRINCIPAL INVESTIGATOR: Kongming Wu, M.D., Ph.D.

CONTRACTING ORGANIZATION: Jefferson Medical College
Philadelphia, PA 19107

REPORT DATE: October 2013

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2013		2. REPORT TYPE Annual Report		3. DATES COVERED 30Sep2012-29Sep2013	
4. TITLE AND SUBTITLE The Role of Retinal Determination Gene Network (RDGN) in Hormone Signaling Transduction and Prostate Tumorigenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0303	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Kongming Wu, M.D., Ph.D. E-Mail: david.strahan@jefferson.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Jefferson Medical College Philadelphia, PA 19107				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES Dr. Kongming Wu terminated from TJU effective 7/1/13. A change of PI request is in its final stages of approval/amendment with Margaret Lesnow, Assistance Agreement Team 4, USAMRAA.					
14. ABSTRACT Prostate cancer is the most frequent malignancy and the second leading cause of cancer-related death among men in the United States. Based on the unique characteristics that those prostate epithelia are dependent on androgen for growth and survival, androgen deprivation therapy (ADT) has been a first choice of prostate cancer treatment. Despite early success to suppress prostate tumor growth, ADT eventually fails leading to recurrent tumor growth in a hormone-refractory manner, even though AR remains to function in hormone-refractory prostate cancer. We identified a member of androgen receptor (AR) co-regulator, named dachshund (<i>dac</i>). <i>dac</i> was originally discovered as a dominant inhibitor of hyperactive growth factor receptors in genetic screens. RDGN pathway, consisting of the <i>dachshund</i> (<i>dac</i>), <i>eyes absent</i> (<i>eya</i>), <i>eyeless</i> , and <i>sine oculis</i> (<i>so</i>) (<i>Six</i>) genes DACH1 is structurally distinct to the current known tumor suppressors. We propose this unique function as a new type of tumor suppressor and refer to DACH1 as a "commandeering tumor suppressor." Recently, we reported that expression of DACH1 is lost in human prostate cancer tissues and restoration of DACH1 inhibited ligand induced AR activity. Although the abnormal expressions of RDGN genes have been reported in prostate cancer, the precise role of RDGN in prostate cancer is not clear.					
15. SUBJECT TERMS None listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 13	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
Introduction	4
Body	5
Key Research Accomplishments	10
Reportable Outcomes	11
Conclusion	12
References	13

INTRODUCTION

Prostate cancer is the most frequent malignancy and the second leading cause of cancer-related death among men in the United States. Based on the unique characteristics that those prostate epithelia are dependent on androgen for growth and survival, androgen deprivation therapy (ADT) has been a first choice of prostate cancer treatment. Despite early success to suppress prostate tumor growth, ADT eventually fails leading to recurrent tumor growth in a hormone-refractory manner, even though AR remains to function in hormone-refractory prostate cancer. We identified a member of androgen receptor (AR) co-regulator, named dachshund (*dac*). *dac* was originally discovered as a dominant inhibitor of hyperactive growth factor receptors in genetic screens. RDGN pathway, consisting of the *dachshund* (*dac*), *eyes absent* (*eya*), *eyeless*, and *sine oculis* (*so*) (*Six*) genes DACH1 is structurally distinct to the current known tumor suppressors. We propose this unique function as a new type of tumor suppressor and refer to DACH1 as a “commandeering tumor suppressor.” Recently, we reported that expression of DACH1 is lost in human prostate cancer tissues and restoration of DACH1 inhibited ligand induced AR activity. Although the abnormal expressions of RDGN genes have been reported in prostate cancer, the precise role of RDGN in prostate cancer is not clear.

BODY

Aim 1. Evaluate the physiological role of DACH1 in prostate gland development and ErbB2-induced prostate tumor. Investigating the role of DACH1 as a physiological co-repressor of AR will be conducted on transgenic mice in which the *Dach1* gene is flanked by loxP sites (*Dach1^{fl/fl}*) and crossed with Probasin-Cre (Pb-Cre) to generate double transgenic mice, those mice will be crossed with Probasin-erbB2Δ (Pb-erbB2) transgenic mice to create triple transgenic mice, *Dach1^{fl/fl}/Pb-Cre/ Pb-erbB2Δ*.

Using *Dach1^{fl/fl}*/Probasin-Cre bi-transgenic mice endogenous *Dach1* was shown to serve as a key endogenous restraint to prostate epithelial cell growth, and migration.




Figure 1. Transgenic deletion of *Dach1* in the prostate epithelial cells enhances cellular proliferation A-B) Analysis of bi-transgenic mice encoding *Dach1^{fl/fl}*/Probasin-Cre immunohistochemical staining for Ki67 in ventral prostate shown at 10x and 40x. Data is shown for mean \pm SEM N>500 cells.

Conditional *Dach1* gene knockout in the prostate demonstrates a role for endogenous *Dach1* as an inhibitor of cellular proliferation and inducer of apoptosis. In order to determine the potential role for *Dach1* in prostatic cellular proliferation *in vivo*, bi-transgenic mice were generated. The *Dach1^{fl/fl}* mice were intercrossed with Probasin-Cre mice, in which Cre recombinase is expressed in the basal and luminal epithelial cells of the prostate. Immunohistochemical staining demonstrated the loss of *Dach1* in both the anterior and ventral prostates of the bi-transgenic mice. An analysis of cellular proliferation and apoptosis was conducted. Ki67 staining, a surrogate measure for cellular proliferation, was significantly increased in the PEC of the *Dach1^{fl/fl}*/Probasin-Cre mice (Fig. 1). TUNEL staining was conducted to assess the effect of endogenous *Dach1* on cellular survival *in vivo*. The percentage of apoptotic cells was reduced ~3-fold in the *Dach1^{-/-}* prostate (Fig. 2). Consistent with the finding that DACH1 inhibited cyclin A2 and cyclin E1, immunohistochemical staining demonstrated that the abundance of cyclin A2 and cyclin E1 was increased in the *Dach1^{-/-}* PEC.





Figure 2. Transgenic deletion of *Dach1* in the prostate epithelial cells reduces cellular apoptosis. A-B) Analysis of bi-transgenic mice encoding *Dach1^{fl/fl}*/Probasin-Cre TUNEL staining for ventral prostate shown at 10x and 40x. Data is shown for mean \pm SEM N>500 cells.

DACH1 inhibits prostate cancer cellular migration and persistence of migratory directionality. In order to determine whether DACH1-regulated prostate cancer cellular migration, the effect of DACH1 on the ability of PC3 cells to traverse a membrane was assessed. DACH1 expression in PC3 cells reduced transwell migration by >90% (Fig. 3A, B) and deletion of the DACH1 DS domain abrogated the effect on cell migration (Fig. 3B). In order to define further the distinct components of cell migration regulated by DACH1 expression, video microscopy was conducted to determine the distance and effect of DACH1 on prostate cancer cellular migratory directionality. DACH1 inhibited the distance traveled by PC3 cells. The effect was abrogated by the deletion of the DS domain (Fig. 3C). The velocity of migration was also reduced by DACH1 requiring the DACH1 DS domain (Fig. 3D).

In order to define the mechanisms by which DACH1 inhibited cellular migration, microarray analysis was conducted of key growth factor receptor and cytokine/chemokine signaling pathways known to promote cellular proliferation and migration. A module of secreted cytokine signaling was selectively repressed by DACH1, including IL-6, IL-8, and CXCL6, 1, 2, 5 and IL-6 (Fig. 3E). Deletion of the DS domain abrogated DACH1-mediated repression of IL-8 and IL-6 expression (Fig. 3E).

In order to determine the mechanisms by which DACH1 reduced the cytokine signaling module, we considered the possibility that DACH1 may inhibit the transcription of CXCL genes. We examined the IL-6 and IL-8 promoters. Both IL-6 and IL-8 were repressed in a dose-dependent manner by DACH1, and repression required the DS domain (Fig. 3F, G).


In order to determine whether DACH1-mediated repression of IL-8 was oncogene specific, we assessed the isogenic oncogene transformed prostate cancer cell lines, in which DACH1 expression was reduced. Microarray analysis of the isogenic prostate cancer cell lines in tissue culture (Fig. 4A) or *in vivo* in tumors derived from FVB mice, demonstrated increased expression of IL-6 and IL-8 (CXCL1) in each of the lines transformed by distinct oncogenes (c-Myc, NeuT, H-Ras, V-Src). Immunohistochemical staining of the extirpated tumors demonstrated a significant inverse correlation between DACH1 and the abundance of CXCL1 (KC), IL-6 and CXCR2 (the receptor for CXCL1) (Fig. 4C-E).



Dach1 inhibition of cellular migration involves secreted cytokines (IL-6, CXCL1). In order to determine whether endogenous DACH1 regulated the secretion of the cytokine signaling mRNA module identified in human prostate cancer cells in tissue culture, the prostatic epithelium of the bi-transgenic mice (*Dach1^{fl/fl}/probasin Cre*) was analyzed.

Aim 2. Examine the role of DACH1 in prostate cancer cell AR signaling transduction, proliferation, migration and invasion *in vitro*:

DACH1 inhibited androgen therapy-resistant prostate cancer (CRPC) tumor growth in mice and contact-independent growth, via a helix-turn-helix DNA interaction domain which was required to both repress CRPC growth and inhibit expression and secretion of a CXCL gene cluster (IL-8, IL-6).



DACH1 inhibits CRPC contact-independent growth. In order to define the genetic cell-cycle targets of DACH1, and to determine whether DACH1 was capable of inhibiting AR negative prostatic cancer cell contact-independent growth, the PC3 cell line was stably transduced with an expression vector encoding DACH1, or a mutant of DACH1 deleted of the DS domain. Microarray analysis was conducted of the cell lines (Fig. 5A). Interrogation of the cell cycle control proteins demonstrated that, unlike several other cell types in which cyclin D1 is a direct-target of DACH1 repression, the *cyclin E1* and *cyclin A2* gene were repressed in PC3 cells (Fig. 5A). Deletion of the DS domain abrogated repression of cyclin A2 mRNA expression (Fig. 5A). We examined the possibility that the *cyclin E1* and *cyclin A2* genes were direct transcriptional targets of DACH1. The *cyclin E1* and *cyclin A2* promoter linked to a luciferase reporter gene was examined for responsiveness to DACH1. Transfection of a DACH1 expression vector with either the cyclin E1 or cyclin A2 promoter-reporter in PC3 cells induced a dose-dependent repression dependent upon the DS domain (Fig. 5B, C). Antibodies directed to the DACH1 protein demonstrated the presence of DACH1 in PC3 cells stably expressing DACH1 or the Δ DS domain (Fig. 5D).




Figure 5. DACH1 inhibits AR-negative prostate cancer cell proliferation and contact independent growth by the DS domain. A) Treeview display of microarray gene expression studies conducted on PC3 cells stably expressing either vector control, DACH1 or DACH1 ΔDS. The cell cycle control proteins are shown with the relative abundance, demonstrated and a color scale is shown. DACH1 inhibits cyclin A2 and cyclin E1 abundance. B) Cyclin E1 and C) cyclin A2 promoter reporter activity assessed in PC3 cells upon transfection of expression vectors encoding either the DACH1 or ΔDS mutant of DACH1. D) Phase contrast using immunofluorescent microscopy for PC3 stable cell lines for DACH1 and DAPI for nuclear staining. E) The cellular proliferation rate determined by MTT assay or F) cell counting. Data are mean ±SEM for N>5 throughout.


Aim 3: Investigate the role of DACH1 in tumor growth *in vivo* using xenograft models.

DACH1 inhibition of prostate cancer cellular invasion and migration required CXCL gene expression. DACH1 expression was reduced in metastatic human prostate cancer.

DACH1 inhibits CRPC and PEC growth *in vivo*. In order to determine whether DACH1 inhibited CRPC tumor growth *in vivo*, tumor size of DACH1 transduced PC3 cells was determined weekly after implantation (Fig. 2A). The tumor size increased in the vector control, but was reduced by the expression of DACH1, with an approximately 50% decrease in tumor volume at week 7. Deletion of the DS domain abrogated the reduction of tumor growth in nude mice. The tumor weight was similarly reduced, approximately ~50% *in vivo* (Fig. 6B), whereas deletion of the DS domain abrogated the inhibition of tumor weight. The CWR22Rv1 line was derived from a relapsed human prostate cancer CWR22 xenograft (1). This line encodes a ligand independent AR variant that arises by splicing of cryptic exons (2). The CWR22Rv1 cells express the AR variant and are p53 positive, unlike PC3 cells, which are AR negative and p53 negative. Re-expression of DACH1 in CWR22Rv1 cells reduced tumor growth in mice approximately 50% at 5 weeks post implantation (Fig. 2C). Deletion of the DACH1 DS domain reduced, but did not abrogate the inhibition of cell growth, suggesting distinguishable domains of DACH1 may be involved in the inhibition of cellular growth in AR negative vs. AR positive cells *in vivo*. The weight of the tumor was reduced >80% by DACH1 expression (Fig. 2D, E).

Aim 4. Analyze the expression of DACH1, Eya1 and Six1 in human prostate tumor samples.

In order to determine whether a clinical correlate existed for DACH1-mediated repression of cellular migration, we hypothesized that DACH1 expression may be lost in metastatic prostate cancer. Interrogation of clinical databases demonstrated the relative abundance of DACH1 was reduced in prostate cancer compared with benign prostate disease, with significant further reduction in metastatic prostate cancer samples (Fig. 4F) (above).



KEY RESEARCH ACCOMPLISHMENTS

1. Conditional *Dach1* gene knockout in the prostate demonstrates a role for endogenous Dach1 as an inhibitor of cellular proliferation and inducer of apoptosis.
2. DACH1 inhibits prostate cancer cellular migration and persistence of migratory directionality.
3. DACH1 inhibits CRPC and PEC growth *in vivo*.
4. *Dach1* inhibition of cellular migration involves secreted cytokines (IL-6, CXCL1).
5. DACH1 was reduced in prostate cancer compared with benign prostate disease, with significant further reduction in metastatic prostate cancer samples.

REPORTABLE OUTCOMES

Manuscripts

- Chen K, Wu K, Wang L, Jiao X, Ju X, Li Z, Ertel A, Addya S, McCue P, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG. *Androgen therapy resistant prostate cancer growth and invasion is inhibited by the Cell-Fate Factor Dachshund via a CXCL Signaling Module*. (In Review).

Abstracts and Presentations

- Li Z, Hu J, Chen K, Wu J, Pestell RG. DACH1 inhibited prostate cancer cellular proliferation and Interleukon-6 signaling. AACR 103rd Annual Meeting, March 31 – April 4, 2012, Chicago, IL.
- Wang J, Cai S, Chen K, Sun Y, Li S, Pestell RG, Wu K. Regulation of AR transcriptional activity and prostate cancer cellular proliferation by DACH1/Eya1/Six1 pathway. AACR Annual Meeting, April 6-10, 2013, Washington, DC.

Licenses applied for and/or issued

- Nil

Degrees obtained that are supported by this award

- Nil

Development of cell lines, tissue or serum repositories

- Nil

Informatics, such as databases and animal models, etc.

- Animal model first prostate specific Dach1 gene deletion mouse – Dach1^{fl/fl} Probasin Cre

Funding applied for based on work supported by this award

- Nil

Employment or research opportunities applied for and/or received based on experience/training supported by this award.

- Post-Doctoral training by Dr. Chen

CONCLUSION

Using *Dach1*^{fl/fl}/Probasin-Cre bi-transgenic mice endogenous *Dach1* was shown to serve as a key endogenous restraint to prostate epithelial cell growth, and migration.

These studies suggest that endogenous Dach1 is the major endogenous inhibitor of cytokine signaling. Cytokines and chemokines have broad effects on cellular inflammation, migration, invasion and growth. Inflammation is an important early change in human prostate cancer. Establishing that Dach1 is the key inhibitor of cytokine signaling in the prostate will therefore be an important next goal.

Furthermore, we will need to establish whether reduction of endogenous DACH1 occurs early in PIN lesions as humans as inflammation is a common early event in human PIN lesions.

REFERENCES

1. Sramkoski RM, *et al.* (1999) A new human prostate carcinoma cell line, 22Rv1. *In Vitro Cell Dev Biol Anim* 35(7):403-409.
2. Hu R, *et al.* (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Res* 69(1):16-22.